A New Era in TGCT Treatment: Novel Targeted Therapies and Their Effect on Shared Decision Making
E-Publication E-Publication

A New Era in TGCT Treatment: Novel Targeted Therapies and Their Effect on Shared Decision Making


Released:
11/26/19
Expires:
11/25/20

Maximum Credits:

0.75
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

E-Publication E-Publication
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.
Released:
11/26/19

Expires:
11/25/20

Maximum Credits:
0.75
E-Publication E-Publication
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

Released:
11/26/19
Expires:
11/25/20


Maximum Credits:
0.75


Overview: This accredited CME publication explores the latest therapeutic advances and emerging science for the management of tenosynovial giant cell tumor (TGCT). In addition to discussing the safety and efficacy of recently approved and emerging therapies, it also addresses how to implement the principles of shared decision making in the routine care of patients with TGCT. Audio clips provide insights from expert faculty, William D. Tap, MD, about translating clinical trial data into practice.

CME Information:

Faculty
William D. Tap, MD
Chief, Sarcoma Medical Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY

Activity Planners
Iwona Misiuta, PhD, MHA
Clinical Content Manager
Med-IQ
Baltimore, MD
 
Rebecca L. Julian, MS, ELS
Senior Manager, Editorial
Med-IQ
Baltimore, MD
 
Samantha Gordon
CME Specialist
Med-IQ
Baltimore, MD
 
Kathryn Schaefer, MSN, RN, CPHRM
Senior Manager, Accreditation and Compliance
Med-IQ
East Lansing, MI

Writer
Patrick McCarthy
Bronxville, NY
 
Learning Objectives
Upon completion, participants should be able to:

  • Describe the mechanisms of action, efficacy, and safety of emerging therapies in clinical development for TGCT
  • Select appropriate treatment strategies for patients with TGCT, including in the context of clinical trial enrollment, based on recent clinical evidence, expert perspectives, and patient preferences

Target Audience
This activity is intended for medical oncologists, surgeons, and rheumatologists.
 
Statement of Need
TGCT is a rare, local, aggressive, heterogeneous, benign tumor associated with joint destruction, inflammation, pain, and swelling, which can result in significant impairment to physical function and have a profound effect on patients’ quality of life. It has an estimated annual incidence of 11 to 50 cases per 1 million individuals. Until recently, the current standard of care for TGCT was surgical resection of the tumor; however, not every person is a candidate for surgery. Research has shown that TGCT cells overexpress colony-stimulating factor 1 (CSF1), which leads to the recruitment of CSF1 receptor (CSF1R)-positive tumor-associated macrophages and drives tumor growth and progression. This finding has led to the development of CSF1R inhibitors. Clinicians need to be aware of the clinical data on the efficacy and safety of these agents, as well as their potential use, so that they are prepared to incorporate them into clinical practice as they become available.

Providership Statement
Provided by Med-IQ.

Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Med-IQ designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.

Medium/Method of Participation
This CME activity consists of a 0.75-credit online publication. To receive credit, read the introductory CME material, read the publication, and complete the post-survey, evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.

Initial Release Date: November 26, 2019
Expiration Date: November 25, 2020
Estimated Time to Complete This Activity: 45 minutes

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
 
Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation. 
 
William D. Tap, MD
Royalty: Companion Diagnostics
Receipt of intellectual property right/patent holder: Companion Diagnostics
Consulting fees/advisory boards: Blueprint Medicines, Daiichi Sankyo, Co., Ltd., Deciphera, Eli Lilly and Company, EMD Serono, Inc., Nanno Carrier
Ownership interest (stocks/stock options – excluding mutual funds): Atropos Therapeutics, Certis Oncology Solutions

The writer, peer reviewers, and activity planners have no financial relationships to disclose.

Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, Med-IQ has a policy to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
 
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

Contact Information        
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email info@med-iq.com.          
                      
System Requirements
Desktop

Mobile

  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.
 
Disclaimer
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy policy, please visit: www.med-iq.com/privacy-policy.html.

Acknowledgment of Commercial Support
This activity is supported by an educational grant from Daiichi Sankyo, Inc.

Copyright
© 2019 Med-IQ, Inc.

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or email info@med-iq.com. For technical assistance, please refer to our support manual.

We recently updated our Privacy Notice and Terms of Use.